A number of reports have provided support for the therapeutic potential in the development of inhibitors of the PCAF Brd (p300/CBP Associated Factor) owing to the link with a variety of diseases including cancer,20–22 HIV,20,23–26 and neuro-inflammation20,27 PCAF has been predicted to be a highly druggable target by Vidler et al.28 This evidence concerns the gene EP300 and cancer.